- Home
- ISPC vs CERO Comparison
ISPC vs CERO Comparison
Compare ISPC & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- CERO
- Stock Information
- Founded
- ISPC 2009
- CERO 2017
- Country
- ISPC United States
- CERO United States
- Employees
- ISPC N/A
- CERO N/A
- Industry
- ISPC Precision Instruments
- CERO
- Sector
- ISPC Health Care
- CERO
- Exchange
- ISPC Nasdaq
- CERO Nasdaq
- Market Cap
- ISPC 3.1M
- CERO 3.1M
- IPO Year
- ISPC 2021
- CERO N/A
- Fundamental
- Price
- ISPC $1.25
- CERO $0.89
- Analyst Decision
- ISPC
- CERO Strong Buy
- Analyst Count
- ISPC 0
- CERO 1
- Target Price
- ISPC N/A
- CERO $11.00
- AVG Volume (30 Days)
- ISPC 141.2K
- CERO 4.4M
- Earning Date
- ISPC 04-14-2025
- CERO 04-15-2025
- Dividend Yield
- ISPC N/A
- CERO N/A
- EPS Growth
- ISPC N/A
- CERO N/A
- EPS
- ISPC N/A
- CERO N/A
- Revenue
- ISPC $9,291,115.00
- CERO N/A
- Revenue This Year
- ISPC $35.93
- CERO N/A
- Revenue Next Year
- ISPC N/A
- CERO N/A
- P/E Ratio
- ISPC N/A
- CERO N/A
- Revenue Growth
- ISPC N/A
- CERO N/A
- 52 Week Low
- ISPC $1.02
- CERO $0.53
- 52 Week High
- ISPC $11.80
- CERO $171.00
- Technical
- Relative Strength Index (RSI)
- ISPC 47.69
- CERO 49.91
- Support Level
- ISPC $1.15
- CERO $0.53
- Resistance Level
- ISPC $1.23
- CERO $1.42
- Average True Range (ATR)
- ISPC 0.16
- CERO 0.12
- MACD
- ISPC 0.02
- CERO 0.07
- Stochastic Oscillator
- ISPC 28.67
- CERO 40.19
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.